

## Supplementary Information for

# Disulfiram-Loaded Niosomes Reduces Cancerous Phenotypes in Oral Squamous Cell Carcinoma Cells

Melika Zangeneh Motlagh, D.D.S.<sup>1,2#</sup>, Nazanin Mahdavi, D.D.S., M.Sc.<sup>1,3</sup>, Zohreh Miri-Lavasani, M.Sc.<sup>2#</sup>, Pouyan Amin-  
ishakib, D.D.S., M.Sc.<sup>1,3</sup>, Mahsa Khoramipour, M.Sc.<sup>2</sup>, Mandana Kazem Arki, M.Sc.<sup>2</sup>, Niloufar Rezaei,  
M.Sc.<sup>2</sup>, Nikoo Hossein-Khannazer, Ph.D.<sup>2</sup>, Massoud Vosough, M.D., Ph.D.<sup>4,5\*</sup>

1. Department of Oral and Maxillofacial Pathology, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
2. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Department of Pathology, Cancer Institute Hospital, IKHC, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
5. Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden

**Table S1:** Design of experiments for Niosome-loaded DSF

| A. Design of experiments using central composite design method to optimize the N-DSF |            |                         |           |       |        |
|--------------------------------------------------------------------------------------|------------|-------------------------|-----------|-------|--------|
| Number                                                                               | Lipid (μM) | Surfactant: Cholesterol | Size (nm) | PDI   | EE (%) |
| 1                                                                                    | 200        | 2                       | 200.2     | 0.17  | 68.79  |
| 2                                                                                    | 250        | 1                       | 291.4     | 0.275 | 77.23  |
| 3                                                                                    | 300        | 0.5                     | 332.9     | 0.121 | 65.11  |
| 4                                                                                    | 200        | 0.5                     | 230.8     | 0.248 | 51.35  |
| 5                                                                                    | 250        | 1                       | 217.9     | 0.248 | 72.23  |
| 6                                                                                    | 250        | 1                       | 206       | 0.219 | 71.1   |
| 7                                                                                    | 200        | 1                       | 169.9     | 0.221 | 55.5   |
| 8                                                                                    | 250        | 2                       | 178       | 0.187 | 82     |
| 9                                                                                    | 250        | 0.5                     | 270.3     | 0.145 | 63.51  |
| 10                                                                                   | 250        | 1                       | 194.7     | 0.205 | 70.4   |
| 11                                                                                   | 300        | 2                       | 263.2     | 0.292 | 84.4   |

Received: 26/December/2022, Revised: 19/April/2023, Accepted: 04/May/2023

#These authors equally contributed to this work.

\*Corresponding Address: Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran


Email: masvos@royaninstitute.org

Table S1: Continued

## B. ANOVA statistical analysis

| Source             |        | F value  | P value, prob>f |
|--------------------|--------|----------|-----------------|
| Particle size (nm) |        |          |                 |
| Model              | 17.59  | 0.0034   | Significant     |
| A                  | 48.57  | 0.0009   |                 |
| B                  | 21.93  | 0.0054   |                 |
| A2                 | 7.43   | 0.0415   |                 |
| PDI                |        |          |                 |
| Model              | 11.68  | 0.0087   | Significant     |
| B                  | 6.80   | 0.0477   |                 |
| AB                 | 34.73  | 0.0020   |                 |
| B2                 | 13.44  | 0.0145   |                 |
| EE (%) of DSF      |        |          |                 |
| Model              | 54.96  | 0.0002   | Significant     |
| A                  | 118.32 | 0.0001   |                 |
| B                  | 138.17 | < 0.0001 |                 |
| A2                 | 18.07  | 0.0081   |                 |

1A; Niosomal compositions were optimized utilizing RSM and a Central Composite design. Niosome particle size (nm), PDI, and EE% were investigated as a function of two selected numerical parameters [lipid content (M) and Surfactant per cholesterol molar ratio]. In order to derive the polynomial equation, design-expert was used (version 7.0.10, Stat-Ease, Inc., Minneapolis, MN, USA). Evaluation of experimental results versus predictions. 1B; Quadratic polynomial modeled response ( $P \leq 0.05$ ). Statistically, the model worked. Particle size was affected by lipid content and surfactant-to-cholesterol molar ratio. PDI variance analysis shows that the quadratic model is adequate due to polynomial responses. This statistically significant model ( $P \leq 0.05$ ) implies that surfactant-to-cholesterol ratio affects PDI. SF's lipid content and surfactant molar ratio affected EE (%). RSM; Response surface methodology, N-DSF; Disulfiram-loaded Niosomes PDI; Polydispersity index, and EE; Entrapment efficiency.



**Fig.S1:** Response surfaces as a function of the lipid content ( $\mu\text{M}$ ) and molar ratio surfactant per cholesterol. **A.** Size, **B.** PDI, and **C.** EE (%) of DSF. PDI; Polidispersity index, EE; Entrapment efficiency, and DSF; Disulfiram.